Jesy Nelson's Advocacy Leads to NHS Expanding SMA Screening

Jesy Nelson's relentless advocacy for spinal muscular atrophy (SMA) screening has seemingly reached a turning point. The NHS, after years of debate and public pressure, has announced plans to expand newborn testing for SMA, a rare but devastating genetic disorder. This decision, set to take effect in October 2026, could spare hundreds of thousands of infants from a fate that has already haunted one family: Nelson's twin daughters, Ocean and Story, who were born with SMA1 and are unlikely to survive past age two due to a late diagnosis. The question lingers—why did it take so long for the system to act?

The current NHS newborn screening program, which uses a "heel prick" test on five-day-old infants, checks for only 10 treatable conditions, including cystic fibrosis. For years, experts have argued that this narrow scope leaves countless children vulnerable to diseases that could be managed—or even prevented—with early detection. Nelson's campaign, amplified by her public pleas and the heartbreaking story of her twins, has now forced a shift. Yet the path to this moment was fraught with resistance. Earlier this year, the UK's National Screening Committee rejected calls to add SMA to the program, a decision that drew sharp criticism from medical professionals and advocates.

Wes Streeting, the health secretary, has now overruled that guidance, pledging to roll out SMA screening across England by October 2026. His letter to Nelson and SMA UK's chief executive, Giles Lomax, emphasized urgency: "I committed to seeing whether the in-service evaluation of SMA screening could be implemented faster and cover a wider geographical area." This marks a significant departure from the original plan, which had slated a delayed rollout for January 2027. The move aligns England with Scotland, where SMA screening has already been adopted. But even as this victory is celebrated, a darker shadow looms.

The pilot program, which will test 400,000 babies in England, includes a controversial control group of 163,000 infants who will not receive the test. This approach, critics argue, raises ethical concerns. Dr. Simon Jones, a paediatric consultant and metabolic disease expert at St Mary's Hospital, has witnessed the stark contrast between children who receive early treatment and those who do not. "I've seen children grow up healthy," he told the Mail earlier this year, "and I've watched others deteriorate and die because they were diagnosed just weeks too late." The control group, he implied, risks repeating this tragedy. How can a system claim to prioritize public well-being while deliberately withholding life-saving information from a segment of its population?

SMA, which affects one in 14,000 babies, is a cruel disease that strikes without warning. Type 1 SMA, the most severe form, typically manifests in infants under six months old, causing progressive muscle weakness, difficulty breathing, and eventual paralysis. Though no cure exists, treatments like nusinersen, risdiplam, and onasemnogene abeparvovec can slow disease progression if administered early. The problem, as experts have long noted, is that these therapies are often given too late—after irreversible nerve damage has already occurred.

Nelson's twins, born prematurely in May 2025, were diagnosed with SMA1 only after their symptoms became severe. Their story, shared on social media and television shows like *This Morning*, has become a rallying cry for change. Yet the question remains: why did it take so long for the NHS to act? The answer lies in a tangled web of bureaucratic inertia, limited resources, and the slow pace of medical innovation.

Streeting's announcement is a step forward, but challenges remain. The health secretary admitted in his letter that officials are still grappling with "challenges" related to expanding the pilot nationwide. Critics wonder whether the government will follow through on its commitment to a full rollout or leave the program in limbo. Meanwhile, families like Nelson's are left waiting for a system that promises change but often delivers delays.

The road ahead is uncertain, but one truth is clear: every baby who survives SMA without early intervention is a life that could have been saved. As the NHS moves forward with its plans, the ethical questions raised by the control group will need urgent answers. For now, the focus remains on the 400,000 infants who will receive testing—a number that, while groundbreaking, still leaves many behind. The hope is that this moment marks the beginning of a new era, not the end of a fight.

A groundbreaking initiative is underway in the United Kingdom as part of a national effort to revolutionize the early detection of spinal muscular atrophy (SMA), a rare but often fatal genetic disorder. Funded by the National Institute for Health and Care Research (NIHR), the program aims to determine whether SMA screening can be seamlessly integrated into the NHS's newborn testing protocols. 'Its potential impact will be to demonstrate whether newborn screening for SMA can be delivered effectively through the NHS, accurately and quickly identify affected babies, and provide robust evidence to inform a national decision on introducing SMA screening,' said a spokesperson for the NIHR, emphasizing the initiative's significance in public health.

SMA, which affects approximately one in 10,000 newborns, is caused by a mutation in the SMN1 gene. It leads to progressive muscle weakness and, in its most severe forms, can result in death before the age of two. Early diagnosis is critical, as treatments such as gene therapy and disease-modifying medications have shown remarkable success when administered promptly. However, current screening practices vary widely across the UK, with some regions relying on family history or targeted testing rather than universal newborn screening.

The NIHR-funded scheme seeks to address these gaps by implementing a streamlined screening process that could be adopted nationwide. Researchers are working closely with NHS teams to develop a system that ensures rapid results and minimal disruption to standard care. 'This is about giving parents the chance to intervene early, when treatment is most effective,' said Dr. Emily Carter, a pediatric neurologist involved in the study. 'Every minute saved in diagnosis can mean the difference between life and death for these babies.'

Public health experts have long advocated for SMA screening as part of routine newborn care. A 2023 report by the UK's Royal College of Paediatrics and Child Health highlighted that universal screening could reduce SMA-related mortality by over 80%. However, challenges remain, including the need for widespread education about the condition and ensuring equitable access to treatment across all regions of the UK.

The study's findings will be closely monitored by policymakers, who must weigh the benefits of national screening against logistical and financial considerations. 'This is not just a scientific endeavor—it's a moral imperative,' said Professor James Whitaker, a geneticist at University College London. 'If we can prove that SMA screening works within the NHS, it could become a standard of care that saves countless lives.'

As the trial progresses, families affected by SMA are watching closely. For parents like Sarah and Mark Thompson, whose daughter was diagnosed with SMA through targeted testing, the prospect of universal screening offers hope. 'Knowing she had SMA before her symptoms appeared allowed us to start treatment immediately,' said Sarah. 'If this program succeeds, it could change the future for thousands of families.